Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the ...

1), their portfolios have more protection from erosion due to generic entry. The focus on biologics, many of which are also specialty products, of both companies earns them peer-group-leading ...

Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2 ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

Biocon has reported a consolidated net profit of Rs 25 crore in Q3 FY25, which is significantly lower as compared with the PAT of Rs 660 crore posted in Q3 FY24.

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

NEWARK, Del, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The global biologics market is projected to witness substantial growth, with an estimated worth of USD 450.2 billion in 2025, reaching USD 1,077.2 ...

Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as ...